O(bΣ) Removal by H, CO, NO, CH, and CH in the 300-800 K Temperature Range.

Rate constants for the removal of O bΣ by collisions with species relevant to combustion, H, CO, NO, CH and CH have been measured in the temperature range 297-800 K. O(bΣ) was produced from ground-state molecular oxygen by photoexcitation pulses from a tunable dye laser, and the deactivation kinetics were followed by observing the temporal behavior of the bΣ-XΣ fluorescence. The removal rate constants for H, CO, NO, CH, and CH could be represented by the modified Arrhenius expressions k = (1.

O(bΣ) Quenching by O, CO, HO, and N at Temperatures of 300-800 K.

Rate constants for the removal of O(bΣ) by collisions with O, N, CO, and HO have been determined over the temperature range from 297 to 800 K. O(bΣ) was excited by pulses from a tunable dye laser, and the deactivation kinetics were followed by observing the temporal behavior of the bΣ-XΣ fluorescence. The removal rate constants for CO, N, and HO were not strongly dependent on temperature and could be represented by the expressions k = (1.

Lymphocytic Infiltration as a Prognostic Factor in Patients With Colon Cancer.

Host-defense mechanisms may have an important role in predicting the outcome of colorectal cancer patients. We designed our study to evaluate the possible prognostic significance of the presence of lymphocytic infiltration (LI) and subgroups of lymphocytes (CD3 and CD20) in the primary tumors. We randomly selected 195 patients operated for colorectal carcinoma from a larger cohort of 1527 patients with colorectal cancer.

COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients.

COX2 expression correlates with high-grade breast cancer, but the clinical significance and possible prognostic influence in these patients have not been studied in depth. Our goal was to evaluate the significance of COX2 expression in a group of patients with high-grade breast cancer. Three hundred and three patients (median age 55; age range 25-95 years) with high-grade breast cancer entered this retrospective study.